Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

Merck & Co. Inc. has decided that it will not commercialize its own version of Sanofi's Lantus (insulin glargine) in the US, even though the product was already tentatively approved by the US FDA in 2017.

"After a comprehensive assessment of the current and future market environment for insulin glargine, which included an assessment of anticipated pricing and cost of production, we made the business decision to terminate our agreement on the commercialization of Lusduna pen and vial," Merck said in a statement to Scrip